Cargando…

Radiation Dose-Effect Relation in Patients with Esophageal Squamous Cell Carcinoma: A National Cancer Center Data and Literature-Based Analysis

INTRODUCTION: Despite receiving definitive chemoradiotherapy (dCRT) with radiation dose (RTD) of 50.4 Gy, survival of esophageal carcinoma was dismal. The effect of RTD in cancer control and radiotoxicity, and the extent to which local-regional control (LRC) influenced survival remain vague. This st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Weiming, Li, Chen, Deng, Wei, Ni, Wenjie, Chang, Xiao, Gao, Linrui, Wang, Shijia, Wang, Xin, Xiao, Zefen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617729/ https://www.ncbi.nlm.nih.gov/pubmed/36317125 http://dx.doi.org/10.1155/2022/2438270

Ejemplares similares

Effect of Adjuvant Radiation Dose on Survival in Patients with Esophageal Squamous Cell Carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
por: Li, Chen, et al.
Publicado: (2021)

A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer
por: Li, Chen, et al.
Publicado: (2019)

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol
por: Chang, Xiao, et al.
Publicado: (2020)

Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
por: Li, Chen, et al.
Publicado: (2021)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Nomogram-Based Survival Predictions and Treatment Recommendations for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Upfront Surgery
por: Zhu, Jie, et al.
Publicado: (2022)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy
por: Yu, Shufei, et al.
Publicado: (2016)

Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two‐center study
por: Ni, Wenjie, et al.
Publicado: (2019)

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma
por: Wang, Qifeng, et al.
Publicado: (2013)

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
por: Yang, Siran, et al.
Publicado: (2022)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2017)

Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)
por: Zhang, Wencheng, et al.
Publicado: (2020)

A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol
por: Gao, Lin-rui, et al.
Publicado: (2020)

S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial
por: Wang, Xin, et al.
Publicado: (2020)

Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
por: Deng, Yuxia, et al.
Publicado: (2017)

Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis
por: Liu, Xianghe, et al.
Publicado: (2018)

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells
por: Ding, Wen-Xiu, et al.
Publicado: (2019)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
por: Zhang, Wencheng, et al.
Publicado: (2017)

Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma
por: Wang, Qifeng, et al.
Publicado: (2019)

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
por: So, Tsz Him, et al.
Publicado: (2020)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy
por: Wang, Qifeng, et al.
Publicado: (2015)

Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: A post hoc analysis of a randomized controlled trial
por: Ni, Wenjie, et al.
Publicado: (2022)

Targeting valosin‐containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma
por: Luo, Hui, et al.
Publicado: (2019)

Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses
por: Shueng, Pei‐Wei, et al.
Publicado: (2022)

Outcomes and Prognostic Factors of Salvage Radiation for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma
por: Zhang, Chi, et al.
Publicado: (2021)

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma
por: Oh, Dongryul, et al.
Publicado: (2016)

Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma
por: Qiu, Jianjian, et al.
Publicado: (2023)

A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
por: Deng, Wei, et al.
Publicado: (2017)

Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma: A single institution experience
por: Ke, Te-Min, et al.
Publicado: (2018)

Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma
por: Pai, Chu-Pin, et al.
Publicado: (2022)

Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Xin, et al.
Publicado: (2023)

A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019)

Correction to: A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cdg6j49ivifap6si64alrd3u21